The Impact of KETO5 XOGenius Beverage on Markers of Physiological and Neurocognitive Health

NCT06318390 | Completed DMC

• 1 other identifier: 2023-0271
• Study Type: interventional
• Target: 6
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objectives of this application are to 1) investigate the effect of increased daily consumption of the Keto5 XOGenius beverage on outcomes associated with elevated risk for various neurocognitive and pathophysiological conditions/diseases. And 2) to investigate the effect of daily consumption of the Keto5 XOGenius beverage on the following variables: waist circumference, body weight, and body mass index (BMI).

Conditions

Cardiovascular Diseases; Hypertension; Cognitive Decline; Diet; Healthy

Keywords

endothelial function; brain blood flow; cognition

Outcome Measures

Primary Outcomes (11)

• Endothelial Function

  Flow medicated dilation of the brachial artery (% change)

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

• Neurocognitive Function

  Performance on the NIH Toolbox Cognitive battery

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

• Peripheral systolic blood pressure

  standard blood pressure measures (mmHg)

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

• Plasma concentration of Total Cholesterol (Total-C)

  assessment of Total Cholesterol

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

• Arterial stiffness

  assessment of pulse wave velocity and pulse wave analysis

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

• Peripheral diastolic blood pressure (diastolic)

  standard blood pressure measures (mmHg)

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

• Peripheral mean blood pressure (mean)

  standard blood pressure measures (mmHg)

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

• Plasma concentration of High Density Lipoprotein (HDL-C)

  assessment of High Density Lipoprotein (HDL-C)

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

• Plasma concentration of Low Density Lipoprotein (LDL-C)

  assessment of Low Density Lipoprotein (LDL-C)

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

• Plasma concentration of Very Low Density Lipoprotein (VLDL-C)

  assessment of Low Density Lipoprotein (VLDL-C)

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

• Plasma concentration of Triglycerides (TG)

  assessment of Triglycerides (TG)

  baseline, 2 weeks post daily consumption of Keto5 XOgenius, & 4 weeks of daily keto5 XOgenius consumption

Study Arms (1)

Keto5 XOGenius Beverage

EXPERIMENTAL

Keto5 XOGenius Beverage contains natural ingredients that are high in the Ketone β-OHB content and has anti-inflammatory and antioxidant properties

Dietary Supplement: XO Genius

Interventions

XO Genius DIETARY_SUPPLEMENT

This is a beverage powder that is high in healthy ingredients that are believed to be beneficial for physiological health

Keto5 XOGenius Beverage

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Men and women who are between the ages of 18-50

You may not qualify if:

• Food allergies
• Type I diabetes/Type II diabetes, and/or a history of hypoglycemia.
• History of irritable bowel syndrome or inflammatory bowel disease.
• Currently taking any medications that are designed to treat a cardiovascular or metabolic condition
• Pregnant women
• Breast feeding women
• Allergy to spandex/lycra/latex
• Anemia
• Use of prescription stimulants

Sponsors & Collaborators

• The University of Texas at Arlington: lead

Study Sites (1)

UT Arlington - Science and Engineering Innovation and Research Building

Arlington, Texas, 76019, United States

Location

MeSH Terms

Conditions

Cardiovascular Diseases; Hypertension; Cognitive Dysfunction

Condition Hierarchy (Ancestors)

Vascular Diseases; Cognition Disorders; Neurocognitive Disorders; Mental Disorders

Study Officials

• Robert M Brothers, PhD

  University of Texas at Arlington

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: March 12, 2024
• First Posted: March 19, 2024
• Study Start: August 1, 2023
• Primary Completion: May 15, 2025
• Study Completion: May 31, 2025
• Last Updated: September 26, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)